It has been an incredible year for Worldwide Cancer Research scientists around the globe, who have all been busy making exciting new discoveries that will help us reach a day when no life is cut short by cancer. Here are the top breakthroughs in cancer research made possible by Curestarters in 2025.
How a high-fat diet could influence cancer spread:
A very high-fat diet could make it easier for cancer to spread through the body. Recent cancer research has uncovered a surprising link – that special molecules that help our blood to clot also seem to play a key role in how cancer spreads. This discovery by Dr Héctor Peinado and his team at the Spanish National Cancer Research Centre (CNIO) could help scientists unlock new ways to treat and manage cancer – by understanding not just how tumours grow, but how what we eat could influence their spread.
Crucial progress for a rare childhood brain cancer:
Professor Adrian Bracken at Trinity College Dublin is part of an international team who are making strides in finding new ways to treat Diffuse Midline Glioma, an aggressive brain cancer that mainly affects children. The team have made new discoveries about the specific genetic mutation that causes nearly all DMG cases, and found a weak spot in DMG cells that could be a critical target for new treatments.
Using the science behind antidepressants to spark a new cancer cure:
We love researchers that think outside the box to find new cancer cures and in 2025 Dr Simona Polo in Italy did just that. Exploring how an antidepressant interacts with a certain protein led to her making an exciting breakthrough about how cancer drugs could also target that molecule. The team have developed a new drug molecule that could one day become a new cancer cure.
A step closer to improving immunotherapy for melanoma:
Dr Adam Hurlstone and his team in Manchester have made a crucial breakthrough about how melanoma cells become resistant to immunotherapy, and how to stop it. They hope these findings will bring us closer to a new cure for patients who have advanced melanoma and have few other treatment options.
Hope at the end of the rainbow for new breast cancer cures:
Professor Johanna Ivaska and her team in Finland have been able to look at breast cancer cells moving in more detail than ever before thanks to a powerful new tool named after an old Finnish fairy tale about rainbows. Understanding how breast cancer cells spread is vital to help more people survive this disease. The innovative tool helped make a new cancer breakthrough about the exact molecules involved in breast cancer metastasis. Professor Ivaska hopes this will lead to new cures to block breast cancer spread.
How do cancer breakthroughs lead to real-world treatments?
All new cures begin with curiosity. By asking questions about cancer, and finding out the answers, our researchers make breakthroughs in our understanding of the disease. This discovery research is the first step in the research journey.
Once a breakthrough is made and we have some new information about cancer, the next stage is translational research where that knowledge is used to create something new, such as a new cancer treatment. Finally that new cure needs tested in clinical trials to make sure it works and is safe for patients.
This whole pipeline is critical, but a breakthrough marks a pivotal moment in the journey from the lab to the clinic. It can be the “Eureka” moment that takes research in a new direction or shows the path towards a new cure.
Even more cancer breakthroughs are on the horizon
The Next Frontier: How Cutting-Edge Science is Redefining Cancer Treatment
The landscape of cancer therapy is undergoing a revolutionary transformation, moving beyond the traditional pillars of surgery, chemotherapy, and radiation. Today, a new era of precision medicine is yielding treatments that are more effective, less toxic, and increasingly personalized. This update explores the most promising frontiers in oncology, where scientific innovation is turning once-intractable cancers into manageable conditions.
1. The Immunotherapy Evolution: Beyond First-Generation Checkpoint Inhibitors
Immunotherapy, which harnesses the body’s own immune system to fight cancer, continues to be a powerhouse. While drugs targeting PD-1 and CTLA-4 (like pembrolizumab and ipilimumab) are now standard for many cancers, the focus has shifted to overcoming resistance.
- Next-Gen Checkpoints & Bispecifics: Researchers are targeting new immune “brakes” like LAG-3, TIGIT, and TIM-3. The LAG-3 inhibitor relatlimab, combined with nivolumab, is now approved for advanced melanoma, offering a new option where PD-1 inhibitors alone may fail . Furthermore, bispecific T-cell engagers (BiTEs) are creating a direct bridge between cancer cells and immune cells. Blincyto (blinatumomab) for leukemia has paved the way, and new BiTEs show promise in solid tumors like prostate cancer .
- Engineered Cell Therapy 2.0: CAR-T therapy has been a miracle for blood cancers. The next generation aims to conquer solid tumors (like breast or brain cancer) and improve safety. Strategies include:
- CAR-NK Cells: Using Natural Killer cells instead of T cells, which may be safer and easier to produce “off-the-shelf” .
- Armored CAR-Ts: Cells engineered to secrete cytokines (like IL-18) to overcome the immunosuppressive tumor microenvironment .
Reference: American Association for Cancer Research (AACR) on next-gen immunotherapy: https://www.aacr.org/patients-caregivers/progress-against-cancer/next-generation-of-cancer-immunotherapy/
2. The Rise of Radiopharmaceutical Therapy: “Seeking and Destroy” from Within
This burgeoning field combines a tumor-targeting molecule with a radioactive payload, delivering radiation directly to cancer cells while largely sparing healthy tissue.
- The Success of Pluvicto: The 2022 FDA approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for metastatic prostate cancer marked a watershed moment. In patients who had exhausted other options, Pluvicto significantly improved survival by targeting PSMA, a protein on prostate cancer cells . This has spurred intense research into similar agents for other cancers expressing specific markers.
Reference: NEJM publication on Pluvicto’s Phase III trial results: https://www.nejm.org/doi/full/10.1056/NEJMoa2107322
3. Antibody-Drug Conjugates (ADCs): Becoming More Precise and Potent
ADCs are “smart bombs”—monoclonal antibodies that deliver a potent chemotherapy drug directly to tumors. The latest developments focus on improving their design and expanding their reach.
- New Targets and Linker Technology: New ADCs are targeting a wider array of tumor antigens (like TROP-2, with drugs like sacituzumab govitecan for breast cancer). Advances in “linker” technology—the part that connects the drug to the antibody—allow for more stable delivery and more potent payloads to be released only inside the cancer cell .
- The “Trojan Horse” Effect: Some ADCs are now designed to have “bystander effects,” where the cytotoxic payload can diffuse into neighboring tumor cells, even those not expressing the target, potentially overcoming heterogeneity.
Reference: Nature Reviews Cancer on ADC engineering advances: https://www.nature.com/articles/s41568-023-00589-z
4. AI and Digital Pathology: The Diagnostic Revolution
Treatment begins with accurate diagnosis. Artificial Intelligence is now being integrated into pathology, analyzing tissue slides with superhuman precision to detect subtle patterns, predict genetic mutations from images, and forecast patient outcomes. This not only speeds up diagnosis but also helps identify the best therapeutic pathway from the outset.
Reference: FDA authorization of an AI-powered prostate cancer detection tool: https://www.fda.gov/news-events/press-announcements/fda-authorizes-software-can-help-identify-prostate-cancer
5. Minimal Residual Disease (MRD) Detection: A New Benchmark for Care
The ability to detect microscopic traces of cancer (MRD) after treatment via liquid biopsies (blood tests analyzing circulating tumor DNA) is changing how we manage cancer. A positive MRD test can signal the need for additional (“adjuvant”) therapy to prevent recurrence, while a negative result may allow some patients to avoid unnecessary treatments. This is rapidly becoming a critical endpoint in clinical trials and a guide for personalized decision-making.
Reference: ASCO review on the use of MRD in solid tumors: https://ascopubs.org/doi/10.1200/EDBK_320535
Challenges and the Path Forward
Despite the excitement, challenges remain: the immense cost of novel therapies, ensuring equitable access, and managing unique side effects. Furthermore, overcoming tumor resistance to these advanced agents is the next great scientific hurdle.
The future lies in combination strategies—intelligently pairing immunotherapies, targeted drugs, ADCs, and radiopharmaceuticals based on a tumor’s unique molecular profile. With each breakthrough, the paradigm shifts further from a one-size-fits-all war on cancer to a personalized, precise, and increasingly potent campaign against hundreds of different diseases.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult with their healthcare team for information and decisions regarding their treatment.